Bioxyne Limited ( (AU:BXN) ) has shared an update.
Bioxyne Limited has upgraded its revenue forecast for FY 2025 to $25 million, reflecting a 267% increase in revenue for the first half of the fiscal year. This growth is attributed to major contracts, a growing customer base, and an expanding product range, alongside a focus on maintaining positive cashflow and EBITDA. The company’s Breathe Life Science division plays a pivotal role, following its GMP licence approval. Bioxyne aims to expand its market share, customer base, and scale up operations while introducing new products into its distribution channels.
More about Bioxyne Limited
Bioxyne Limited is an Australian life sciences company specializing in pharmaceutical and consumer health products. It focuses on manufacturing novel medicines, with significant efforts in medical cannabis products, and holds a Good Manufacturing Practice Licence for Psilocybin and MDMA. The company also markets the Dr Watson® brand in Australia and Europe, and distributes its Lactobacillus fermentum PCC® probiotic globally.
YTD Price Performance: -6.67%
Average Trading Volume: 1,939,284
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$57.38M
Learn more about BXN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com